rospedРоссийский педиатрический журнал имени М.Я. СтуденикинаM.Ya. Studenikin Russian Pediatric JournalФГАУ «НМИЦ здоровья детей» Минздрава России10.46563-1-2026-45-52XVHEJMrosped-2031Research ArticleНАУЧНЫЕ ОБЗОРЫREVIEWSНарушения слуха у детей с мукообструктивными болезнями лёгкихHearing disorders in children with muco-obstructive lung diseaseshttps://orcid.org/0009-0003-0618-1500СоколоваВ. Н.SokolovaVera N.

Соколова Вера Николаевна, канд. мед. наук, ст. науч. сотр. лаб. научных основ оториноларингологии

e-mail: sokolova-doki@mail.ru

Vera N. Sokolova, MD, PhD, senior researcher, Laboratory of scientific foundations of otorhinolaryngology

e-mail: sokolova-doki@mail.ru

sokolova-doki@mail.ruhttps://orcid.org/0000-0002-8968-1935МалявинаУ. С.MalyavinaUlyana S.

Малявина Ульяна Станиславовна, доктор мед. наук, врач-­ оториноларинголог, зав. лаб. научных основ оториноларингологии

e-mail: nouse@inbox.ru

nouse@inbox.ruhttps://orcid.org/0000-0002-2367-9920СимоноваО. И.SimonovaOlga I.

Симонова Ольга Игоревна, доктор мед. наук, зав. пульмонологическим отд-м, проф. каф. педиатрии и общественного здоровья; проф. каф. педиатрии и детской ревматологии; руководитель кабинета муковисцидоза

e-mail: oisimonova@mail.ru

oisimonova@mail.ruhttps://orcid.org/0000-0002-1629-3157КондратчиковД. С.KondratchikovDmitriy S.

Кондратчиков Дмитрий Сергеевич, канд. мед. наук, зав. оториноларингологическим отд-м

e-mail: kondratchikov@gmail.com

kondratchikov@gmail.comФГАУ «Национальный медицинский исследовательский центр здоровья детей» Минздрава РоссииРоссияNational Medical Research Center for Children’s HealthRussian FederationФГАУ «Национальный медицинский исследовательский центр здоровья детей» Минздрава России; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет); ГБУЗ города Москвы «Морозовская детская городская клиническая больница» Департамента здравоохранения г. МосквыРоссияNational Medical Research Center for Children’s Health; I.M. Sechenov First Moscow State Medical University (Sechenov University); Morozov Children’s Municipal Clinical HospitalRussian Federation202627032026114552Copyright © Соколова В.Н., Малявина У.С., Симонова О.И., Кондратчиков Д.С., 20262026Соколова В.Н., Малявина У.С., Симонова О.И., Кондратчиков Д.С.Sokolova V.N., Malyavina U.S., Simonova O.I., Kondratchikov D.S.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rosped.ru/jour/article/view/2031Введение

Введение. Муковисцидоз (МВ) и первичная цилиарная дискинезия — наследственные заболевания, сопровождающиеся нарушением мукоцилиарного клиренса и хроническим поражением респираторного тракта. Цель: представить современные сведения о патогенезе тугоухости при мукообструктивных болезнях лёгких и определить риски ототоксичности аминогликозидов при модулирующей таргетной терапии МВ у детей. Проведён анализ данных, представленных в международных базах данных (Scopus, Web of Science, PubMed) и российских научных библиотеках (eLIBRARY.RU, КиберЛенинка). Установлены различия в характере тугоухости при МВ и первичной цилиарной дискинезии у детей. Для цилиарной дискинезии характерна кондуктивная потеря слуха, в то время как при МВ сохраняется риск сенсоневральной тугоухости, обусловленной ототоксичностью аминогликозидов на фоне таргетной терапии. Персонализация лечения и профилактики этих форм патологии у детей способствуют уменьшению рисков, что определяет необходимость разработки специализированных алгоритмов наблюдения. Установлена необходимость дифференцированного подхода к мониторингу слуховой функции у больных с мукообструктивными болезнями лёгких.Участие авторов: Соколова В.Н. — концепция и дизайн исследования; Соколова В.Н., Малявина У.С., Симонова О.И. — сбор и обработка материала; Соколова В.Н., Малявина У.С. — написание текста; Симонова О.И., Кондратчиков Д.С. — редактирование. Все соавторы — утверждение окончательного варианта статьи, ответственность за целостность всех частей статьи.Финансирование. Исследование не имело финансовой поддержки.Конфликт интересов. Авторы подтверждают отсутствие конфликта интересов.

Поступила 23

Поступила 23.01.2026Принята к печати 10.02.2026Опубликована 27.02.2026

Introduction

Introduction. Cystic fibrosis (CF) primary ciliary dyskinesia are hereditary diseases characterized by impaired mucociliary clearance and chronic respiratory tract involvement. Aim. To present current literature data on the pathogenesis of hearing loss in muco-obstructive lung diseases and detect risks of aminoglycoside ototoxicity under the modulating therapy for CF in children. There was performed an analysis of scientific literature data from international databases (Scopus, Web of Science, PubMed) and Russian scientific libraries (eLIBRARY.RU, CyberLeninka). Differences in the nature of hearing loss in СF and primary ciliary dyskinesia were established. For the primary ciliary dyskinesia there is characteristic hearing loss, whereas in CF the risk of sensorineural hearing loss persists due to the ototoxicity of aminoglycosides caused by targeted therapy. Personalized treatment and prevention of these forms of pathology in children help reduce risks, necessitating the development of specialized monitoring algorithms. The need for a differentiated approach to monitoring auditory function in patients with muco-obstructive lung diseases has been established.Contributions: Sokolova V.N. — concept and design of the study; Sokolova V.N., Malyavina U.S., Simonova O.I. — material collection and processing; Sokolova V.N., Malyavina U.S. — writing the text; Simonova O.I., Kondratchikov D.S. — editing the text. All authors approved the final version of the manuscript and are responsible for the integrity of all parts of the article.Acknowledgments. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.

Received

Received: January 23, 2026

Accepted

Accepted: February 10, 2026

Published

Published: February 27, 2026

обзордетимуковисцидозпервичная цилиарная дискинезиятугоухость: сенсоневральная кондуктивнаядисфункция слуховой трубымукоцилиарный клиренсхронический средний отитототоксичностьаминогликозидыreviewchildrencystic fibrosisprimary ciliary dyskinesiahearing loss: sensorineural hearing lossconductive hearing lossEustachian tube dysfunctionmucociliary clearancechronic otitis mediaototoxicityaminoglycosidesReferencesLucas J.S., Carroll M. Primary ciliary dyskinesia and cystic fibrosis: different diseases require different treatment. Chest. 2014; 145(4): 674–6. https://doi.org/10.1378/chest.13-2590Lucas J.S., Carroll M. Primary ciliary dyskinesia and cystic fibrosis: different diseases require different treatment. Chest. 2014; 145(4): 674–6. https://doi.org/10.1378/chest.13-2590Cockx M., Gouwy M., Van Damme J., Struyf S. Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases. Cell. Mol. Immunol. 2018; 15(4): 312–23. https://doi.org/10.1038/cmi.2017.118Cockx M., Gouwy M., Van Damme J., Struyf S. Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases. Cell. Mol. Immunol. 2018; 15(4): 312–23. https://doi.org/10.1038/cmi.2017.118Pereira R., Barbosa T., Cardoso A.L., Sá R., Sousa M. Cystic fibrosis and primary ciliary dyskinesia: Similarities and differences. Respir. Med. 2023; 209: 107169. https://doi.org/10.1016/j.rmed.2023.107169Pereira R., Barbosa T., Cardoso A.L., Sá R., Sousa M. Cystic fibrosis and primary ciliary dyskinesia: Similarities and differences. Respir. Med. 2023; 209: 107169. https://doi.org/10.1016/j.rmed.2023.107169Kinghorn B., Rosenfeld M., Sullivan E., Onchiri F.M., Brown M.D., Szczesniak R., et al. Comparison of longitudinal outcomes in children with primary ciliary dyskinesia and cystic fibrosis. Ann. Am. Thorac. Soc. 2024; 21(12): 1723–32. https://doi.org/10.1513/AnnalsATS.202311-1008OCKinghorn B., Rosenfeld M., Sullivan E., Onchiri F.M., Brown M.D., Szczesniak R., et al. Comparison of longitudinal outcomes in children with primary ciliary dyskinesia and cystic fibrosis. Ann. Am. Thorac. Soc. 2024; 21(12): 1723–32. https://doi.org/10.1513/AnnalsATS.202311-1008OCKartal Y., Bozdemir Özel C., Çakmak A., Sonbahar Ulu H., İnal İnce D., Ademhan Tural D., et al. The relationship between lung function, exercise capacity, oxidant and antioxidant response in primary ciliary dyskinesia and cystic fibrosis. Turk. J. Pediatr. 2024; 66(3): 309–322. https://doi.org/10.24953/turkjpediatr.2024.4581Kartal Y., Bozdemir Özel C., Çakmak A., Sonbahar Ulu H., İnal İnce D., Ademhan Tural D., et al. The relationship between lung function, exercise capacity, oxidant and antioxidant response in primary ciliary dyskinesia and cystic fibrosis. Turk. J. Pediatr. 2024; 66(3): 309–22. https://doi.org/10.24953/turkjpediatr.2024.4581Whitsett J.A. Airway epithelial differentiation and mucociliary clearance. Ann. Am. Thorac. Soc. 2018; 15(Suppl. 3): 143–8. https://doi.org/10.1513/AnnalsATS.201802-128AWWhitsett J.A. Airway epithelial differentiation and mucociliary clearance. Ann. Am. Thorac. Soc. 2018; 15(Suppl. 3): 143–8. https://doi.org/10.1513/AnnalsATS.201802-128AWHill D.B., Button B., Rubinstein M., Boucher R.C. Physiology and pathophysiology of human airway mucus. Physiol. Rev. 2022; 102(4): 1757–836. https://doi.org/10.1152/physrev.00004.2021Hill D.B., Button B., Rubinstein M., Boucher R.C. Physiology and pathophysiology of human airway mucus. Physiol. Rev. 2022; 102(4): 1757–836. https://doi.org/10.1152/physrev.00004.2021Захарова Г.П., Янов Ю.К., Шабалин В.В. Мукоцилиарная система верхних дыхательных путей. СПб.: Диалог; 2010. https://elibrary.ru/vtqwdnZakharova G.P., Yanov Yu.K., Shabalin V.V. The Mucociliary System of the Upper Respiratory Tract [Mukotsiliarnaya sistema verkhnikh dykhatel’nykh putei]. St. Petersburg: Dialog; 2010. https://elibrary.ru/vtqwdn (in Russian)Капранов Н.И., Каширская Н.Ю. Муковисцидоз. В кн.: Розинова Н.Н., Мизерницкий Ю.Л., ред. Хронические заболевания легких у детей. Глава 6. М.: Практика; 2011: 94–107.Kapranov N.I., Kashirskaya N.Yu. Cystic fibrosis. In: Rozinova N.N., Mizernitsky Yu.L., eds. Chronic Lung Diseases in Children. Chapter 6 [Khronicheskie zabolevaniya legkikh u detey. Glava 6]. Moscow: Praktika; 2011: 94–107. (in Russian)Kinghorn B., McNamara S., Genatossio A., Sullivan E., Siegel M., Bauer I., et al. Comparison of multiple breath washout and spirometry in children with primary ciliary dyskinesia and cystic fibrosis and healthy controls. Ann. Am. Thorac. Soc. 2020; 17(9): 1085–93. https://doi.org/10.1513/AnnalsATS.201905-375OCKinghorn B., McNamara S., Genatossio A., Sullivan E., Siegel M., Bauer I., et al. Comparison of multiple breath washout and spirometry in children with primary ciliary dyskinesia and cystic fibrosis and healthy controls. Ann. Am. Thorac. Soc. 2020; 17(9): 1085–93. https://doi.org/10.1513/AnnalsATS.201905-375OCLobo J., Zariwala M.A., Noone P.G. Primary ciliary dyskinesia. Semin. Respir. Crit. Care Med. 2015; 36(2): 169–79. https://doi.org/10.1055/s-0035-1546748Lobo J., Zariwala M.A., Noone PG. Primary ciliary dyskinesia. Semin. Respir. Crit. Care Med. 2015; 36(2): 169–79. https://doi.org/10.1055/s-0035-1546748Кондратьева Е.И., Авдеев С.Н., Киян Т.А., Мизерницкий Ю.Л. Классификация первичной цилиарной дискинезии. Пульмонология. 2023; 33(6): 731–8. https://doi.org/10.18093/0869-0189-2023-33-6-731-738Kondratieva E.I., Avdeev S.N., Kiyan T.A., Mizernitsky Yu.L. Classification of primary ciliary dyskinesia. Pul’monologiya. 2023; 33(6): 731–8. https://doi.org/10.18093/0869-0189-2023-33-6-731-738 (in Russian)Takeuchi K., Abo M., Date H., Gotoh S., Kamijo A., Kaneko T., et al. Practical guide for the diagnosis and management of primary ciliary dyskinesia. Auris Nasus Larynx. 2024; 51(3): 553–68. https://doi.org/10.1016/j.anl.2024.02.001Takeuchi K., Abo M., Date H., Gotoh S., Kamijo A., Kaneko T., et al. Practical guide for the diagnosis and management of primary ciliary dyskinesia. Auris Nasus Larynx. 2024; 51(3): 553–68. https://doi.org/10.1016/j.anl.2024.02.001Hackenberg S., Renson A., Röseler S.M., Baumann I., Topcuoglu M.Y., Hebestreit H. Pädiatrische rhinologie. Laryngorhinootologie. 2024; 103(S 01): 188–213. https://doi.org/10.1055/a-2178-2957Hackenberg S., Renson A., Röseler S.M., Baumann I., Topcuoglu M.Y., Hebestreit H. Pädiatrische rhinologie. Laryngorhinootologie. 2024; 103(S 01): 188–213. https://doi.org/10.1055/a-2178-2957Пальчун В.Т., Гуров А.В., Михалева Л.М., Гордиенко М.В. Современные подходы к оценке значимости хронического воспаления в слизистой оболочке среднего уха. Вестник оториноларингологии. 2018; 83(1): 75–80. https://doi.org/10.17116/otorino201883175-80Palchun V.T., Gurov A.V., Mikhaleva L.M., Gordienko M.V. Modern approaches to assessing the significance of chronic inflammation in the mucous membrane of the middle ear. Vestnik otorinolaringologii. 2018; 83(1): 75–80. https://doi.org/10.17116/otorino201883175-80 (in Russian)Selimoglu E. Aminoglycoside-induced ototoxicity. Curr. Pharm. Des. 2007; 13(1): 119–26. https://doi.org/10.2174/138161207779313731Selimoglu E. Aminoglycoside-induced ototoxicity. Curr. Pharm. Des. 2007; 13(1): 119–26. https://doi.org/10.2174/138161207779313731Lanvers-Kaminsky C., Ciarimboli G. Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin. Pharmacogenomics. 2017; 18(18): 1683–95. https://doi.org/10.2217/pgs-2017-0125Lanvers-Kaminsky C., Ciarimboli G. Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin. Pharmacogenomics. 2017; 18(18): 1683–95. https://doi.org/10.2217/pgs-2017-0125Steyger P.S. Mechanisms of ototoxicity and otoprotection. Otolaryngol. Clin. North Am. 2021; 54(6): 1101–15. https://doi.org/10.1016/j.otc.2021.08.007Steyger P.S. Mechanisms of ototoxicity and otoprotection. Otolaryngol. Clin. North Am. 2021; 54(6): 1101–15. https://doi.org/10.1016/j.otc.2021.08.007Gaafar D., Baxter N., Cranswick N., Christodoulou J., Gwee A. Pharmacogenetics of aminoglycoside-related ototoxicity: a systematic review. J. Antimicrob. Chemother. 2024; 79(7): 1508–28. https://doi.org/10.1093/jac/dkae106Gaafar D., Baxter N., Cranswick N., Christodoulou J., Gwee A. Pharmacogenetics of aminoglycoside-related ototoxicity: a systematic review. J. Antimicrob. Chemother. 2024; 79(7): 1508–28. https://doi.org/10.1093/jac/dkae106Akbari N., Lamooki F.M., Amin M.R., Disnad S.E., Yousefinejad V., Goharnia N. An update on ototoxicity: from a genetic perspective. J. Toxicol. Sci. 2025; 50(6): 245–61. https://doi.org/10.2131/jts.50.245Akbari N., Lamooki F.M., Amin M.R., Disnad S.E., Yousefinejad V., Goharnia N. An update on ototoxicity: from a genetic perspective. J. Toxicol. Sci. 2025; 50(6): 245–61. https://doi.org/10.2131/jts.50.245Saibene A., Urbanelli A., Coudré C., Nitro L., Vroegop A., Lejeune B., et al. Otolaryngological manifestations of cystic fibrosis in children: A systematic review. Int. J. Pediatr. Otorhinolaryngol. 2025; 189: 112238. https://doi.org/10.1016/j.ijporl.2025.112238Saibene A., Urbanelli A., Coudré C., Nitro L., Vroegop A., Lejeune B., et al. Otolaryngological manifestations of cystic fibrosis in children: A systematic review. Int. J. Pediatr. Otorhinolaryngol. 2025; 189: 112238. https://doi.org/10.1016/j.ijporl.2025.112238Yilmaz Yegit C., Ergenekon P., Yanaz M., Ozturk Akar N., Toktas Yavuz F., Molla Kafi H., et al. The association between aminoglycoside exposure and ototoxicity in children with cystic fibrosis. Respiration. 2025; 104(1): 48–57. https://doi.org/10.1159/000541447Yilmaz Yegit C., Ergenekon P., Yanaz M., Ozturk Akar N., Toktas Yavuz F., Molla Kafi H., et al. The association between aminoglycoside exposure and ototoxicity in children with cystic fibrosis. Respiration. 2025; 104(1): 48–57. https://doi.org/10.1159/000541447Jørgensen F., Petruson B., Hansson H.A. Extensive variations in nasal mucosa in infants with and without recurrent acute otitis media. A scanning electron-microscopic study. Arch. Otolaryngol. Head Neck Surg. 1989; 115(5): 571–80. https://doi.org/10.1001/archotol.1989.01860290029010Jørgensen F., Petruson B., Hansson H.A. Extensive variations in nasal mucosa in infants with and without recurrent acute otitis media. A scanning electron-microscopic study. Arch. Otolaryngol. Head Neck Surg. 1989; 115(5): 571–80. https://doi.org/10.1001/archotol.1989.01860290029010Liu X., Cong N., Cheng X., Ma R., Wang J., Huang Y.B., et al. The role of the notch signal pathway in mucosal cell metaplasia in mouse acute otitis media. Sci. Rep. 2017; 7(1): 4588. https://doi.org/10.1038/s41598-017-04639-zLiu X., Cong N., Cheng X., Ma R., Wang J., Huang Y.B., et al. The role of the notch signal pathway in mucosal cell metaplasia in mouse acute otitis media. Sci. Rep. 2017; 7(1): 4588. https://doi.org/10.1038/s41598-017-04639-zMainz J.G., Koitschev A. Pathogenesis and management of nasal polyposis in cystic fibrosis. Curr. Allergy Asthma Rep. 2009; 9(3): 223–30.Mainz J.G., Koitschev A. Pathogenesis and management of nasal polyposis in cystic fibrosis. Curr. Allergy Asthma Rep. 2009; 9(3): 223–30.Wijers C.D., Chmiel J.F., Gaston B.M. Bacterial infections in patients with primary ciliary dyskinesia: Comparison with cystic fibrosis. Chron. Respir. Dis. 2017; 14(4): 392–406. https://doi.org/10.1177/1479972317694621Wijers C.D., Chmiel J.F., Gaston B.M. Bacterial infections in patients with primary ciliary dyskinesia: Comparison with cystic fibrosis. Chron. Respir. Dis. 2017; 14(4): 392–406. https://doi.org/10.1177/1479972317694621Поляков Д.П., Дайхес Н.А., Базанова М.В., Мельяновская Ю.Л. Оценка риска патологии слуха при муковисцидозе у детей. Вестник оториноларингологии. 2024; 89(3): 29–35. https://doi.org/10.17116/otorino20248903129Polyakov D.P., Daikhes N.A., Bazanova M.V., Melyanovskaya Yu.L. Assessment of the risk of hearing pathology in children with cystic fibrosis. Vestnik otorinolaringologii. 2024; 89(3): 29–35. https://doi.org/10.17116/otorino20248903129 (in Russian)Ишанова Ю.С., Зоненко О.Г., Дьяконова И.Н., Шумилов П.В., Рахманова И.В. Объективный контроль слуховой функции у детей, больных муковисцидозом, не предъявляющих жалоб на снижение слуха. Вестник восстановительной медицины. 2018; (3): 97–100. https://elibrary.ru/utxlglIshanova Yu.S., Zonenko O.G., Dyakonova I.N., Shumilov P.V., Rakhmanova I.V. Objective control of hearing ability of children with cystic fibrosis who have not complained of hearing loss. Vestnik vosstanovitelnoy meditsiny. 2018; (3): 97–100. https://elibrary.ru/utxlgl (in Russian)Ghedia R., Ahmed J., Navaratnam A. Hearing loss in children with primary ciliary dyskinesia. Int. J. Pediatr. Otorhinolaryngol. 2018; 104: 161–5. https://doi.org/10.1016/j.ijporl.2017.11.005Ghedia R., Ahmed J., Navaratnam A. Hearing loss in children with primary ciliary dyskinesia. Int. J. Pediatric Otorinolaryngology. 2018; 104: 161–5. https://doi.org/10.1016/j.ijporl.2017.11.005Andersen T.N., Alanin M.C., von Buchwald C., Nielsen L.H. A longitudinal evaluation of hearing and ventilation tube insertion in patients with primary ciliary dyskinesia. Int. J. Pediatr. Otorhinolaryngol. 2016; 89: 164–8. https://doi.org/10.1016/j.ijporl.2016.08.011Andersen T.N., Alanin M.C., von Buchwald C., Nielsen L.H. A longitudinal evaluation of hearing and ventilation tube insertion in patients with primary ciliary dyskinesia. Int. J. Pediatr. Otorhinolaryngol. 2016; 89: 164–8. https://doi.org/10.1016/j.ijporl.2016.08.011Wolter N.E., Dell S.D., James A.L., Campisi P. Middle ear ventilation in children with primary ciliary dyskinesia. Int. J. Pediatr. Otorhinolaryngol. 2012; 76(11): 1565–8. https://doi.org/10.1016/j.ijporl.2012.07.011Wolter N.E., Dell S.D., James A.L., Campisi P. Middle Ear Ventilation in Children with Primary Ciliary Dyskinesia. Int. J. Pediatr. Otorhinolaryngol. 2012; 76(11): 1565–8. https://doi.org/10.1016/j.ijporl.2012.07.011Ghedia R., Ahmed J., Navaratnam A., Harcourt J. No evidence of cholesteatoma in untreated otitis media with effusion in children with primary ciliary dyskinesia. Int. J. Pediatr. Otorhinolaryngol. 2018; 105: 176–80. https://doi.org/10.1016/j.ijporl.2017.12.015Ghedia R., Ahmed J., Navaratnam A., Harcourt J. No evidence of cholesteatoma in untreated otitis media with effusion in children with primary ciliary dyskinesia. Int. J. Pediatr. Otorhinolaryngol. 2018; 105: 176–80. https://doi.org/10.1016/j.ijporl.2017.12.015Rivetti S., Romano A., Mastrangelo S., Attinà G., Maurizi P., Ruggiero A. Aminoglycosides-related ototoxicity: mechanisms, risk factors, and prevention in pediatric patients. Pharmaceuticals (Basel). 2023; 16(10): 1353. https://doi.org/10.3390/ph16101353Rivetti S., Romano A., Mastrangelo S., Attinà G., Maurizi P., Ruggiero A. Aminoglycosides-related ototoxicity: mechanisms, risk factors, and prevention in pediatric patients. Pharmaceuticals (Basel). 2023; 16(10): 1353. https://doi.org/10.3390/ph16101353Шубникова Е.В., Вельц Н.Ю. Ототоксичность аминогликозидов: современные представления. Антибиотики и химиотерапия. 2022; 67(11-12): 79–90. https://doi.org/10.37489/0235-2990-2022-67-11-12-79-90 https://elibrary.ru/fvhsrqShubnikova E.V., Velts N.Yu. Ototoxicity of aminoglycosides: modern concepts. Antibiotiki i khimioterapiya. 2022; 67(11-12): 79–90. https://doi.org/10.37489/0235-2990-2022-67-11-12-79-90 https://elibrary.ru/fvhsrq (in Russian)Bravo O., Ballana E., Estivill X. Cochlear alterations in deaf and unaffected subjects carrying the deafness-associated A1555G mutation in the mitochondrial 12S rRNA gene. Biochem. Biophys. Res. Commun. 2006; 344(2): 511–6. https://doi.org/10.1016/j.bbrc.2006.03.143Bravo O., Ballana E., Estivill X. Cochlear alterations in deaf and unaffected subjects carrying the deafness-associated A1555G mutation in the mitochondrial 12S rRNA gene. Biochem. Biophys. Res. Commun. 2006; 344(2): 511–6. https://doi.org/10.1016/j.bbrc.2006.03.143Ouyang L., Ma L., Feng Y. Protective effects of MET channels on aminoglycosidesand cisplatin-induced ototoxicity. Int. J. Med. Sci. 2025; 22(3): 732–44. https://doi.org/10.7150/ijms.103270Ouyang L., Ma L., Feng Y. Protective effects of MET channels on aminoglycosidesand cisplatin-induced ototoxicity. Int. J. Med. Sci. 2025; 22(3): 732–44. https://doi.org/10.7150/ijms.103270Gaffney P.J., Shetty K.R., Yuksel S., Kaul V.F. Antioxidant therapies in the treatment of aminoglycoside-induced ototoxicity: a meta-analysis. Laryngoscope. 2025; 135(4): 1278–86. https://doi.org/10.1002/lary.31902Gaffney P.J., Shetty K.R., Yuksel S., Kaul V.F. Antioxidant therapies in the treatment of aminoglycoside-induced ototoxicity: a meta-analysis. Laryngoscope. 2025; 135(4): 1278–86. https://doi.org/10.1002/lary.31902Ege T., Tao L., North B.J. The role of molecular and cellular aging pathways on age-related hearing loss. Int. J. Mol. Sci. 2024; 25(17): 9705. https://doi.org/10.3390/ijms25179705Ege T., Tao L., North B.J. The role of molecular and cellular aging pathways on age-related hearing loss. Int. J. Mol. Sci. 2024; 25(17): 9705. https://doi.org/10.3390/ijms25179705Abreu-Silva R.S., Rincon D., Horimoto A.R., Sguillar A.P., Ricardo L.A., Kimura L., et al. The search of a genetic basis for noise-induced hearing loss (NIHL). Ann. Hum. Biol. 2011; 38(2): 210–8. https://doi.org/10.3109/03014460.2010.513774Abreu-Silva R.S., Rincon D., Horimoto A.R., Sguillar A.P., Ricardo L.A., Kimura L., et al. The search of a genetic basis for noise-induced hearing loss (NIHL). Ann. Hum. Biol. 2011; 38(2): 210–8. https://doi.org/10.3109/03014460.2010.513774Huth M.E., Ricci A.J., Cheng E.C. Aminoglycoside antibiotics and the cystic fibrosis transmembrane conductance regulator (CFTR): implications for ototoxicity. J. Biol. Chem. 2011; 286(5): 3699–707. https://doi.org/10.1074/jbc.M110.183673Huth M.E., Ricci A.J., Cheng E.C. Aminoglycoside antibiotics and the cystic fibrosis transmembrane conductance regulator (CFTR): implications for ototoxicity. J. Biol. Chem. 2011; 286(5): 3699–707. https://doi.org/10.1074/jbc.M110.183673Al-Malky G., Dawson D.D., Sirimanna S.J. Aminoglycosideinduced cochlear toxicity in cystic fibrosis: the role of CFTR mutations and the mitochondrial 12S rRNA gene. J. Cyst. Fibros. 2015; 14(4): 448–54. https://doi.org/10.1016/j.jcf.2014.10.003Al-Malky G., Dawson D.D., Sirimanna S.J. Aminoglycosideinduced cochlear toxicity in cystic fibrosis: the role of CFTR mutations and the mitochondrial 12S rRNA gene. J. Cyst. Fibros. 2015; 14(4): 448–54. https://doi.org/10.1016/j.jcf.2014.10.003Thomas J.P., Siracusa C., Kessel A. CFTR modulators and ototoxicity: a pharmacovigilance study. J. Cyst. Fibros. 2019; 18(6): 868–71. https://doi.org/10.1016/j.jcf.2019.05.008Thomas J.P., Siracusa C., Kessel A. CFTR modulators and ototoxicity: a pharmacovigilance study. J. Cyst. Fibros. 2019; 18(6): 868–71. https://doi.org/10.1016/j.jcf.2019.05.008Nussstein H., Urbantat R.M., Fentker K., Loewe A., Duerr J., Haji M., et al. Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on Elexacaftor/Tezacaftor/ Ivacaftor therapy. Eur. Respir. J. 2025; 67(2): 2500616. https://doi.org/10.1183/13993003.00616-2025Nussstein H., Urbantat R.M., Fentker K., Loewe A., Duerr J., Haji M., et al. Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on Elexacaftor/Tezacaftor/ Ivacaftor therapy. Eur. Respir. J. 2025; 67(2): 2500616. https://doi.org/10.1183/13993003.00616-2025Cederroth C.R., Dyhrfjeld-Johnsen J., Canlon B. Pharmacological approaches to hearing loss. Pharmacol. Rev. 2024; 76(6): 1063–88. https://doi.org/10.1124/pharmrev.124.001195Cederroth C.R., Dyhrfjeld-Johnsen J., Canlon B. Pharmacological approaches to hearing loss. Pharmacol. Rev. 2024; 76(6): 1063–88. https://doi.org/10.1124/pharmrev.124.001195Giersch A.B.S., Morton C.C. Newborn screening for deafness/ hard of hearing in the genomic era. Clin. Chem. 2025; 71(1): 54–60. https://doi.org/10.1093/clinchem/hvae193Giersch A.B.S., Morton C.C. Newborn screening for deafness/ hard of hearing in the genomic era. Clin. Chem. 2025; 71(1): 54–60. https://doi.org/10.1093/clinchem/hvae193Kros C.J., Steyger P.S. Aminoglycoside-and cisplatin-induced ototoxicity: mechanisms and otoprotective strategies. Cold Spring Harb. Perspect. Med. 2019; 9(11): a033548. https://doi.org/10.1101/cshperspect.a033548Kros C.J., Steyger P.S. Aminoglycosideand cisplatin-induced ototoxicity: mechanisms and otoprotective strategies. Cold Spring Harb. Perspect. Med. 2019; 9(11): a033548. https://doi.org/10.1101/cshperspect.a033548Fogliano C., Motta C.M., Avallone B. Salicylate attenuates gentamicin-induced ototoxicity and facilitates the recovery in the basilar papilla of the lizard Podarcis siculus. Neurotoxicology. 2022; 93: 301–10. https://doi.org/10.1016/j.neuro.2022.10.013Fogliano C., Motta C.M., Avallone B. Salicylate attenuates gentamicin-induced ototoxicity and facilitates the recovery in the basilar papilla of the lizard Podarcis siculus. Neurotoxicology. 2022; 93: 301–10. https://doi.org/10.1016/j.neuro.2022.10.013McGovern M.M., Cox B.C. Hearing restoration through hair cell regeneration: A review of recent advancements and current limitations. Hear Res. 2025; 461: 109256. https://doi.org/10.1016/j.heares.2025.109256McGovern M.M., Cox B.C. Hearing restoration through hair cell regeneration: A review of recent advancements and current limitations. Hear Res. 2025; 461: 109256. https://doi.org/10.1016/j.heares.2025.109256

The authors declare that there are no conflicts of interest present.